Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal ACWY-CRM conjugate vaccine · 1 trial · 1 indication
Immunogenicity was measured as the percentage of subjects with hSBA seroresponse, directed against each of meningococcal serogroups A, C, W and Y, evaluated by serum bactericidal assay using human complement (hSBA), one month after vaccination (day 29)with MenACWY-CRM or MenACWY-PS vaccine. Seroresponse was defined as: 1. for subjects with a prevaccination hSBA titer \<1:4, a postvaccination hSBA titer ≥1:8; 2. for subjects with a prevaccination hSBA titer ≥1:4, an increase in hSBA titer of at least four times the prevaccination titer.
Safety was assessed in terms of the number of subjects who reported at least one severe systemic reaction after vaccination with MenACWY-CRM or MenACWY-PS from day 1 to day 7 after vaccination.
| Arm | Type | Description |
|---|---|---|
| MenACWY-CRM | EXPERIMENTAL | Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) |
| MenACWY-PS | ACTIVE_COMPARATOR | Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal polysaccharide (PS) vaccine (MenACWY-PS) |
| Name | Type | Description |
|---|---|---|
| Meningococcal ACWY-CRM conjugate vaccine | BIOLOGICAL | MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar. |
| Meningococcal ACWY-PS polysaccharide vaccine | BIOLOGICAL | MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar. |
Inclusion Criteria: * Healthy children 2 to 10 years of age inclusive whose parents or legal guardians gave written informed consent at the time of enrollment; * Available for all visits and telephone calls (parents or legal guardians) scheduled for the study; * Good health as determined by the cli...
The Meningococcal ACWY-CRM conjugate vaccine is an investigational vaccine developed by Novartis AG for the prevention of meningococcal disease. It is designed to protect against meningococcal serogroups A, C, W, and Y. It is a conjugate vaccine, meaning polysaccharide antigens are linked to a carrier protein to generate a stronger immune response.
The Meningococcal ACWY-CRM conjugate vaccine is being developed for the prevention of meningococcal disease, an infectious disease caused by Neisseria meningitidis. The clinical program evaluated it in children 2 to 10 years of age. It targets serogroups A, C, W, and Y.
The Meningococcal ACWY-CRM conjugate vaccine is being developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 3 clinical trial of the vaccine in children.
The Meningococcal ACWY-CRM conjugate vaccine is in Phase 3 development. It is an investigational vaccine and is not approved. One Phase 3 trial has been completed, and no trials are currently active.
The Meningococcal ACWY-CRM conjugate vaccine was studied in one completed Phase 3 trial, NCT00329849, titled Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age. The trial enrolled 1,500 participants in Argentina and was active-controlled and randomized.